Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?

Détails

ID Serval
serval:BIB_8092
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Etude de cas (case report): rapporte une observation et la commente brièvement.
Collection
Publications
Institution
Titre
Has botulinum toxin type A a place in the treatment of spasticity in spinal cord injury patients?
Périodique
Spinal Cord
Auteur(s)
Al-Khodairy A.T., Gobelet C., Rossier A.B.
ISSN
1362-4393 (Print)
ISSN-L
1362-4393
Statut éditorial
Publié
Date de publication
1998
Peer-reviewed
Oui
Volume
36
Numéro
12
Pages
854-858
Langue
anglais
Notes
Publication types: Case Reports ; Journal Article
Publication Status: ppublish
Résumé
OBJECTIVE: To present and discuss treatment of severe spasms related to spinal cord injury with botulinum toxin type A.
DESIGN: A 2-year follow-up study of an incomplete T12 paraplegic patient, who was reluctant to undergo intrathecal baclofen therapy, presenting severe painful spasms in his lower limbs treated with intramuscular injections of botulinum toxin type A.
SETTING: Department of Physical Medicine and Rehabilitation, Hôpital de Gravelone, Sion, Switzerland.
SUBJECT: Single patient case report.
MAIN OUTCOME MEASURE: Spasticity, spasms and pain measured with the modified Ashworth scale, spasm frequency score and visual analogue scale.
RESULTS: Treatment of spasticity with selective intramuscular injections of botulinum toxin type A resulted in subjective and objective improvement.
CONCLUSION: Botulinum toxin type A has its place in the treatment of spasticity in spinal cord injury patients. This treatment is expensive and its effect is reversible. It can complement intrathecal baclofen in treating upper limb spasticity in tetraplegic patients. Tolerance does occur to the toxin. Although high doses of the product are well tolerated, the quantity should be tailored to the patient's need. The minimal amount necessary to reach clinical effects should be adhered to and booster doses at short period intervals should be avoided.
Mots-clé
Botulinum Toxins, Type A/administration & dosage, Botulinum Toxins, Type A/therapeutic use, Humans, Male, Middle Aged, Muscle Spasticity/drug therapy, Neuromuscular Agents/administration & dosage, Neuromuscular Agents/therapeutic use, Quadriplegia/complications, Spinal Cord Injuries/complications, Treatment Outcome
Pubmed
Web of science
Open Access
Oui
Création de la notice
19/11/2007 13:46
Dernière modification de la notice
20/08/2019 15:41
Données d'usage